Kuros Biosciences AG Statistics
Total Valuation
Kuros Biosciences AG has a market cap or net worth of CHF 633.39 million. The enterprise value is 621.08 million.
Market Cap | 633.39M |
Enterprise Value | 621.08M |
Important Dates
The next estimated earnings date is Thursday, November 7, 2024.
Earnings Date | Nov 7, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Kuros Biosciences AG has 37.30 million shares outstanding. The number of shares has increased by 0.34% in one year.
Shares Outstanding | 37.30M |
Shares Change (YoY) | +0.34% |
Shares Change (QoQ) | +2.17% |
Owned by Insiders (%) | 24.20% |
Owned by Institutions (%) | 11.87% |
Float | 25.05M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 9.40 |
PB Ratio | 5.95 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -69.89 |
EV / Sales | 11.82 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -191.28 |
Financial Position
The company has a current ratio of 2.73, with a Debt / Equity ratio of 3.26.
Current Ratio | 2.73 |
Quick Ratio | 2.08 |
Debt / Equity | 3.26 |
Debt / EBITDA | n/a |
Debt / FCF | -0.60 |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -14.32% and return on invested capital (ROIC) is -4.54%.
Return on Equity (ROE) | -14.32% |
Return on Assets (ROA) | -3.77% |
Return on Capital (ROIC) | -4.54% |
Revenue Per Employee | 495,679 |
Profits Per Employee | -83,830 |
Employee Count | 106 |
Asset Turnover | 0.68 |
Inventory Turnover | 1.14 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +767.02% in the last 52 weeks. The beta is 0.86, so Kuros Biosciences AG's price volatility has been lower than the market average.
Beta (5Y) | 0.86 |
52-Week Price Change | +767.02% |
50-Day Moving Average | 13.20 |
200-Day Moving Average | 7.93 |
Relative Strength Index (RSI) | 71.46 |
Average Volume (20 Days) | 287,654 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kuros Biosciences AG had revenue of CHF 52.54 million and -8.89 million in losses. Loss per share was -0.31.
Revenue | 52.54M |
Gross Profit | 46.11M |
Operating Income | -4.69M |
Pretax Income | -7.37M |
Net Income | -8.89M |
EBITDA | -3.05M |
EBIT | -4.69M |
Loss Per Share | -0.31 |
Balance Sheet
The company has 14.28 million in cash and 1.96 million in debt, giving a net cash position of 12.31 million or 0.33 per share.
Cash & Cash Equivalents | 14.28M |
Total Debt | 1.96M |
Net Cash | 12.31M |
Net Cash Per Share | 0.33 |
Equity (Book Value) | 60.18M |
Book Value Per Share | 2.85 |
Working Capital | 21.08M |
Cash Flow
In the last 12 months, operating cash flow was -2.42 million and capital expenditures -832,000, giving a free cash flow of -3.25 million.
Operating Cash Flow | -2.42M |
Capital Expenditures | -832,000 |
Free Cash Flow | -3.25M |
FCF Per Share | -0.09 |
Margins
Gross margin is 87.77%, with operating and profit margins of -8.92% and -16.91%.
Gross Margin | 87.77% |
Operating Margin | -8.92% |
Pretax Margin | -14.03% |
Profit Margin | -16.91% |
EBITDA Margin | -5.80% |
EBIT Margin | -8.92% |
FCF Margin | -6.18% |
Dividends & Yields
Kuros Biosciences AG does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.34% |
Shareholder Yield | -0.34% |
Earnings Yield | -1.83% |
FCF Yield | -0.51% |
Stock Splits
The last stock split was on June 23, 2016. It was a reverse split with a ratio of 0.01.
Last Split Date | Jun 23, 2016 |
Split Type | Reverse |
Split Ratio | 0.01 |